BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
August 04, 2022 14:04 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
August 01, 2022 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
July 12, 2022 08:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for...
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
June 15, 2022 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results
May 11, 2022 16:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022
May 04, 2022 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
April 12, 2022 07:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports 2021 Financial Results and Recent Business Highlights
March 29, 2022 16:05 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
March 24, 2022 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
March 22, 2022 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...